Polymorphism of apolipoprotein A5 is a risk factor for cerebral infarction in type 2 diabetes

Abstract

This study investigated the association of apolipoprotein A5 (apoA5) gene polymorphism at position −1131T>C with cerebral infarction in patients with type 2 diabetes. A total of 256 type 2 diabetic patients without cerebral infarction (T2DM), 220 type 2 diabetic patients with cerebral infarction (T2DMCI) and 340 healthy subjects were recruited from the same region (Hubei province, China). The genotype of apoA5 −1131T〉C was analyzed by polymerase chain reaction, followed by restriction fragment length polymorphism (PCR-RFLP). Total cholesterol, HDL cholesterol, LDL-cholesterol and triglycerides were quantitatively detected by using standard enzymatic techniques. The results showed that the prevalence of the apoA5 −1131C allele was significantly higher in T2DMCI group than that in control group (42.7% versus 31.2%, P<0.01). The carriers of rare C allele had higher TG levels as compared with carriers of common allele in the three groups (P<0.01). Logistic regression models, which were adjusted for age, gender, blood pressure, BMI, FBS, smoking, LDL-C and HDL-C, revealed that patients carrying the apoA5 −1131C allele and CC homozygotes were at high risk for T2DMCI. It was concluded that the apoA5 −1131C allele variant is an independent genetic risk factor for T2DMCI.

Keywords

apolipoprotein A5 / polymorphism / triglyceride / type 2 diabetes / cerebral infarction

References

[1] KraussR. M.. Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am J Med, 1998, 105: 58-62

[2] ForresterJ. S.. Triglycerides: risk factors or fellow traveler?. Curr Opin Cardiol, 2000, 16: 261-264

[3] MalloyM. J., KaneJ. P.. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv Intern Med, 2001, 47: 111-136

[4] PennacchioL. A., OlivierM., HubacekA. J., et al.. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science, 2001, 294: 169-173

[5] van der VlietH. N., SehaapF. G., LevelsJ. H., et al.. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun, 2002, 295: 1156-1159

[6] Fruchart-NajibJ., BaugéE., NiculescuS. L., et al.. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun, 2004, 319: 397-404

[7] SchaapF. G., RensenP. C., VosholP. J., et al.. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem, 2004, 279: 27941-27947

[8] AouizeratB. E., KulkarniM., HeilbronD., et al.. Genetic analysis of a polymorphism in the human apoA-V gene: Effect on plasma lipids. J Lipid Res, 2003, 44: 1167-1173

[9] AustinM. A., TalmudP. J., FarinF. M., et al.. Association of apolipoprotein A5 variants with LDL particle size and triglyceride in Japanese Americans. Biochim Biophys Acta, 2004, 1688: 1-9

[10] BaumL., TomlinsonB., ThomasG. N.. APOA5-1131T>C polymorphism is associated with triglyceride levels in Chinese men. Clin Genet, 2003, 63: 377-379

[11] KaoJ. T., WenH. C., ChienK. L., et al.. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet, 2003, 12: 2533-2539

[12] LaiC. Q., TaiE. S., TanC. E., et al.. The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J Lipid Res, 2003, 44: 2365-2373

[13] LaiC. Q., DemissieS., CupplesL. A., et al.. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J Lipid Res, 2004, 45: 2096-2105

[14] MartinS., NicaudV., HumphriesS. E., et al.. Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochim Biophys Acta, 2003, 1637: 217-225

[15] NabikaT., NasreenS., KobayashiS., et al.. The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis, 2002, 165: 201-204

[16] PennacchioL. A., OlivierM., HubacekJ. A., et al.. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet, 2002, 11: 3031-3038

[17] TalmudP. J., HaweE., MartinS., et al.. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet, 2002, 11: 3039-3046

[18] KlosK. L., HamonS., ClarkA. G., et al.. APOA5 polymorphisms influence plasma triglycerides in young, healthy African Americans and whites of the CARDIA study. J Lipid Res, 2005, 46: 564-570

[19] MaászA., KisfaliP., HorvatovichK., et al.. Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome. Pathol Oncol Res, 2007, 13(3): 243-247

[20] GrarupN., AndersenG.. Gene-environment interactions in the pathogenesis of type 2 diabetes and metabolism. Curr Opin Clin Nutr Metab Care, 2007, 10(4): 420-426

[21] LiJ., XuH., ZhuX.. Association of APOA5 gene polymorphism with levels of lipids and atherosclerotic cerebral infarction in Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (Chinese), 2007, 24(5): 576-578

[22] BarbosaF. A., de LabioR. W., de OliveiraS., et al.. Apolipoprotein A-V gene polymorphism −1131T>C and Alzheimer’s disease. J Alzheimers Dis, 2006, 10(4): 365-369

[23] HavasiV., SzolnokiZ., TaliánG., et al.. Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke. J Mol Neurosci, 2006, 29(2): 177-183

[24] GuardiolaM., FerréR., SalazarJ., et al.. Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation. Clin Chem, 2006, 52(10): 1914-1919

[25] MurrayC. J., LopezA. D.. Mortality by cause for eight regions of the world: Global burden of disease study. Lancet, 1997, 349: 1269-1276